Tratamiento del prurigo nodular con DupilumabNuestra experiencia

  1. Aramburu-González, Aida 1
  2. Julià-Manresa, Marc 2
  3. Izu-Belloso, Rosa 2
  4. Ratón-Nieto, Juan-Antonio 1
  1. 1 Servicio Vasco de Salud-Osakidetza. Organización Sanitaria Integrada Ezkerraldea-Enkarterri-Cruces. Hospital Universitario Cruces. Servicio de Dermatología. Bilbao, España
  2. 2 Servicio Vasco de Salud-Osakidetza. Organización Sanitaria Integrada Bilbao-Basurto. Hospital Universitario Basurto. Servicio de Dermatología. Bilbao, España
Zeitschrift:
Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

ISSN: 0304-4858,  2173-2302

Datum der Publikation: 2024

Ausgabe: 121

Nummer: 1

Seiten: 1-9

Art: Artikel

DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

Zusammenfassung

Sarrera: Prurigo nodularra (PN) larruazaleko gaixotasun pruriginoso eta ahulgarri bat da, larruazaleko nodulu hiperkeratosikoak dituena. Neurodermitis bat da, eta behar terapeutiko ez-ase bat du, pazienteen bizi-kalitatean eragin nabarmena izan dezakeena.Helburuak: Estudio honen helburua dupilumab-aren eraginkortasuna beste tratamendu batzuetarako PN erregogorra duten paziente helduetan ebaluatzea da.Materiala eta metodoak: Atzera begirako estudioa  egin zen, Basurtuko Unibertsitate Ospitalean eta Gurutzetako Unibertsitate Ospitalean, PN diagnostikatutako paziente helduetan, dupilumab bidezko tratamendua 2020ko ekainetik 2021eko azarora arte hasi eta 24 asteko jarraipenarekin. PNren zorroztasuna honako hauen bidez ebaluatu zen: BSA (gorputzaren azaleraren eskala), IGA (ikertzailearen ebaluazio globalaren eskala), NRS (azkuraren kalifikazio numerikoaren eskala), insomnio-eskala eta DLQI (Dermatologiako bizi-kalitatearen indizea).Emaitzak: PN duten sei paziente (% 100 emakumeak; batez besteko adina = 52 urte; maila: 44- 66 urte) dupilumabekin tratatu ziren. Kasu guztietan hobekuntza nabarmena ikusi zen azkuraren eskalan, insomnioan, bizi-kalitatearen indizean, gorputz-azaleraren eremuan eta ikertzailearen ebaluazio-eskala globalean, dupilumab bidezko tratamenduaren ondoren.Ondorioak: Dupilumab tratamendu konbentzionaletarako PN kroniko erregogorrirako tratamendu eraginkor eta segurua izan daiteke.

Bibliographische Referenzen

  • Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ: A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol.2019;80:756-764.http://dx.doi.org/10.1016/j.jaad.2018.09.020.
  • Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163-172. http://dx.doi.org/10.2147/CCID.S188070.
  • Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. http://dx.doi.org/10.1016/j.jaad.2020.04.183.
  • Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567-1575.http://dx.doi.org/10.1016/j.jaad.2020.04.182.
  • Mollanazar NK, Elgash M, Weaver L, Valdes-Rodriguez R, Hsu S. Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis. JAMA Dermatol. 2019;155(1):121-122.http://dx.doi.org/10.1001/jamadermatol.2018.3906.
  • Napolitano M, Fabbrocini G, Scalvenzi M, Nisticò SP, Dastoli S, Patruno C: Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis.2020;81-84. http://dx.doi.org/10.1097/DER.0000000000000517.
  • Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. 2019;155(1):118-120.http://dx.doi.org/10.1001/jamadermatol.2018.3912.
  • Calugareanu A, Jachiet M, Lepelletier C, De Masson A, Rybojad M, Bagot M, Bouaziz JD. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur Acad Dermatol Venereol. 2019;33(8):e303-e304. http://dx.doi.org/10.1111/jdv.15584.
  • Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat. 2020:1-7. http://dx.doi.org/10.1080/09546634.2020.1853024.
  • Ferrucci S, Tavecchio S, Berti E, Angileri L. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2021;32(4):453-454. http://dx.doi.org/10.1080/09546634.2019.1659479.
  • Kovács B, Rose E, Kuznik N, Shimanovich I, Zillikens D, Ludwig RJ, Thaçi D. Dupilumab for treatment- refractory prurigo nodularis. J Dtsch Dermatol Ges. 2020;18(6):618-624. http://dx.doi.org/10.1111/ddg.14107.
  • Romano C. Safety and Effectiveness of Dupilumab in Prurigo Nodularis. J Investig Allergol Clin Immunol. 2020:0. http://dx.doi.org/10.18176/jiaci.0550.
  • Fachler T, Maria Faitataziadou S, Molho-Pessach V. Dupilumab for pediatric prurigo nodularis: A case report. Pediatr Dermatol. 2021;38(1):334-335. http://dx.doi.org/10.1111/pde.14464.
  • Georgakopoulos JR, Croitoru D, Felfeli T, Alhusayen R, Lansang P, Shear NH, Yeung J, Walsh S. Longterm Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A Retrospective Cohort Study. J Am Acad Dermatol. 2021:S0190-9622(21)00363-7.http://dx.doi.org/10.1016/j.jaad.2021.02.038.
  • Liu T, Bai J, Wang S, Ying S, Li S, Qiao J, Fang H. Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy. J Asthma Allergy. 2021;14:175-178. http://dx.doi.org/10.2147/JAA.S300975.
  • Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. Dermatol Ther (Heidelb). 2016 Sep;6(3):397-411. http://dx.doi.org/10.1007/s13555-016-0122-9.
  • Lan CC, Lin CL, Wu CS, Chai CY, Chen WT, Chen GS. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol. 2007 Apr;34(4):237-42. http://dx.doi.org/10.1111/j.1346-8138.2007.00260.x.
  • Taefehnorooz H, Truchetet F, Barbaud A, Schmutz JL, Bursztejn AC. Efficacy of thalidomide in the treatment of prurigo nodularis. Acta Derm Venereol. 2011 May;91(3):344-5. http://dx.doi.org/10.2340/00015555-0997.
  • Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol. 2008 Aug;7(8):769-73.
Fuente de los datos: Dialnet